<DOC>
	<DOCNO>NCT02834884</DOCNO>
	<brief_summary>SPECTArare program aim establish quality assure platform collect clinicopathologically annotate biological material patient primary rare tumor ( 6 new cases/100,000/year ) support biospecimen-based translational research biomarker discovery .</brief_summary>
	<brief_title>SPECTArare : Screening Patients With Rare Tumors Efficient Clinical Trial Access</brief_title>
	<detailed_description />
	<criteria>Patients pathologically confirm rare tumor type Mandatory availability adequate human biological material ( HBM ) : least one FFPE tissue sample either primary tumor and/or recurrent tumor and/or metastasis , obtain adequate surgery biopsy Centrally perform confirmation tumor tissue adequacy term quality/ quantity central screening ; Minimal dataset demographic , clinicopathological treatment data record ; Age â‰¥ 16 year ; Written inform consent accord ICH/GCP national/local regulation ;</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>rare cancer</keyword>
	<keyword>biomarker</keyword>
	<keyword>screen</keyword>
</DOC>